Physician profile
Michael E Brown
NPI 1649286782
$7,792.39
in general payments reported to CMS, 2019-2025
26 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 81% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,458 · 2020: $399 · 2021: $843 · 2022: $986 · 2023: $1,492 · 2024: $1,438 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,106.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,432.71 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $1,829.50 | 2019-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $986.16 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Janssen Products, Lp | $487.26 | 2019-2022 | |
| Emd Serono, INC. | $411.65 | 2019-2025 | Serostim |
| Theratechnologies INC. | $363.33 | 2019-2025 | Egrifta, Trogarzo |
| Janssen Biotech, INC. | $305.37 | 2019-2022 | |
| Abbvie INC. | $192.20 | 2021-2024 | Mavyret |
| Lilly USA, LLC | $163.39 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $109.60 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $100.86 | 2022-2025 | Cresemba, Veozah |
| Octapharma USA, INC. | $91.76 | 2020 | |
| Exact Sciences Corporation | $61.94 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Csl Behring | $36.90 | 2023 | Hizentra |
| Antares Pharma, INC. | $35.76 | 2022-2025 | Xyosted |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22.05 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.47 | 2023 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $19.86 | 2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $17.23 | 2023 | Rexulti |
| Dexcom, INC. | $16.76 | 2024 | Dexcom G6 Transmitter |
| Napo Pharmaceuticals INC | $16.69 | 2024 | Mytesi |
| Grifols USA, LLC | $16.67 | 2022 | |
| Tolmar, INC. | $15.39 | 2023 | |
| Novartis Pharmaceuticals Corporation | $13.42 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.35 | 2023 | Rebyota |
| Pfizer INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.